[1] Franchis R D.Expanding consensus in portal hypertension:report of the Baveno VI Consensus Workshop:stratifying risk and individualizing care for portal hypertension.Journal of Hepatology,2015,63:743-752.
[2] Pettinari I,Vukotic R,Stefanescu H,et al.Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis.Am J Gastroenterol,2019,114:258-266.
[3] Loudin M,Ahn J.Portal vein thrombosis in cirrhosis.L Journal of Clinical Gastroenterology,2017,4:579-585.
[4] Qi X,Guo X,Yoshida EM,et al.Transient portal vein thrombosis in liver cirrhosis.BMC Med,2018,16:82-89.
[5] Nery F,Chevret S,Condat B,et al.Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis:results of a longitudinal study.Hepatology,2015,61:660-667.
[6] Berry K,Taylor J,Liou I W,et al.Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis.Clinical Gastroenterology and Hepatology,2015,13:585-593.
[7] European Association for the Study of the Liver.Electronic address eee.EASL Clinical Practice Guidelines:Vascular diseases of the liver.J Hepatol,2016,64:179-202.
[8] Amitrano L,Guardascione MA,Scaglione M,et al.Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis.Eur J Gastroenterol Hepatol,2012,24:1381-1385.
[9] Stine JG,Shah PM,Cornella SL,et al.Portal vein thrombosis,mortality and hepatic decompensation in patients with cirrhosis:A meta-analysis.World J Hepatol,2015,7:2774-2780.
[10] Zanetto A,Rodriguez-Kastro KI,Germani G,et al.Mortality in liver transplant recipients with portal vein thrombosis-an updated meta-analysis.Transpl Int,2018,31:1318-1329.
[11] Loffredo L,Pastori D,Farcomeni A,et al.Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis:a systematic review and meta-analysis.Gastroenterology,2017,153:480-487 e1.
[12] Chen H,Liu L,Qi X,et al.Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis.Eur J Gastroenterol Hepatol,2016,28:82-89.
[13] Intagliata NM,Henry ZH,Maitland H,et al.Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation.Dig Dis Sci,2016,61:1721-1727.
[14] Qi X,De Stefano V,Li H,et al.Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis:a systematic review and meta-analysis of observational studies.Eur J Intern Med,2015,26:23-29.
[15] Intagliata NM,Caldwell SH,Tripodi A.Diagnosis,development,and treatment of portal vein thrombosis in patients with and without cirrhosis.Gastroenterology,2019,156:1582-1599
[16] Basili S,Pastori D,Raparelli V,et al.Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis:insights for the clinician.Therap Adv Gastroenterol,2018,11:1-10.
[17] La Mura V,Braham S,Tosetti G,et al.Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis.Clin Gastroenterol Hepatol,2018,16:1146-1152 e4.
[18] Priyanka P,Kupec JT,Krafft M,et al.Newer oral anticoagulants in the treatment of acute portal vein thrombosis in Patients with and without Cirrhosis.Int J Hepatol,2018,2018:8432781.
[19] Nagaoki Y,Aikata H,Daijyo K,et al.Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis.Hepatol Res,2018,48:51-58.
[20] Hum J,Shatzel JJ,Jou JH,et al.The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis.Eur J Haematol,2017,98:393-397.
[21] Janczak DT,Mimier MK,McBane RD,et al.Rivaroxaban and Apixaban for initial treatment of acute venous thromboembolism of atypical location.Mayo Clin Proc,2018,93:40-47.
[22] Hanafy AS,Abd-Elsalam S,Dawoud MM.Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis.Vascul Pharmacol,2019,113:86-91.
[23] Kubitza D,Roth A,Becka M,et al.Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban,an oral,direct Factor Xa inhibitor.Br J Clin Pharmacol,2013,76:89-98.
[24] Lv Y,Qi X,He C,et al.Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis:a randomised controlled trial.Gut,2018,67:2156-2168.
[25] Thornburg B,Desai K,Hickey R,et al.Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis:final analysis of a 61-patient cohort.J Vasc Interv Radiol,2017,28:1714-1721 e2.
[26] Jiang TT,Luo XP,Sun JM,et al.Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy vs transjugular intrahepatic portosystemic shunt in patients with cirrhosis and acute portal vein thrombosis.World J Gastroenterol,2017,23:7470-7477.
[27] Qi X,He C,Guo W,et al.Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis:outcomes and predictors in a prospective cohort study.Liver Int,2016,36:667-676.
[28] Qi X,Han G,Fan D.Management of portal vein thrombosis in liver cirrhosis.Nat Rev Gastroenterol Hepatol,2014,11:435-446.
[29] Couri T,Harmath C,Baker T,et al.Acute portal vein thrombosis after liver transplant presenting with subtle ultrasound abnormalities:a case report and literature review.World J Hepatol,2019,11:234-241.
[30] Rossi C,Zambruni A,Ansaloni F,et al.Combined mechanical and pharmacologic thrombolysis for portal vein thrombosis in liver-graft recipients and in candidates for liver transplantation.Transplantation,2004,78:938-940.
[31] De Santis A,Moscatelli R,Catalano C,et al.Systemic thrombolysis of portal vein thrombosis in cirrhotic patients:a pilot study.Dig Liver Dis,2010,42:451-455.
[32] Hall TC,Garcea G,Metcalfe M,et al.Management of acute non-cirrhotic and non-malignant portal vein thrombosis:a systematic review.World J Surg,2011,35:2510-2520.
[33] Bergere M,Erard-Poinsot D,Boillot O,et al.Portal vein thrombosis and liver cirrhosis:Long-term anticoagulation is effective and safe.Clin Res Hepatol Gastroenterol,2019,43:395-402. |
